Sequential Targeting in Crosslinking Nanotheranostics for Tackling the Multibarriers of Brain Tumors
Source abstract
Abstract
Abstract The efficacy of therapeutics for brain tumors is seriously hampered by multiple barriers to drug delivery, including severe destabilizing effects in the blood circulation, the blood–brain barrier/blood–brain tumor barrier (BBB/BBTB), and limited tumor uptake. Here, a sequential targeting in crosslinking (STICK) nanodelivery strategy is presented to circumvent these important physiological barriers to improve drug delivery to brain tumors. STICK nanoparticles (STICK‐NPs) can sequentially target BBB/BBTB and brain tumor cells with surface maltobionic acid (MA) and 4‐carboxyphenylboronic acid (CBA), respectively, and simultaneously enhance nanoparticle stability with pH‐responsive crosslinkages formed by MA and CBA in situ. STICK‐NPs exhibit prolonged circulation time (17‐fold higher area under curve) than the free agent, allowing increased opportunities to transpass the BBB/BBTB via glucose‐transporter‐mediated transcytosis by MA. The tumor acidic environment then triggers the transformation of the STICK‐NPs into smaller nanoparticles and reveals a secondary CBA targeting moiety for deep tumor penetration and enhanced uptake in tumor cells. STICK‐NPs significantly inhibit tumor growth and prolong the survival time with limited toxicity in mice with aggressive and chemoresistant diffuse intrinsic pontine glioma. This formulation tackles multiple physiological barriers on‐demand with a simple and smart STICK design. Therefore, these features allow STICK‐NPs to unleash the potential of brain tumor therapeutics to improve their treatment efficacy.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · Advanced biosensing and bioanalysis techniques · Nanoplatforms for cancer theranostics
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Biochemistry and Molecular Medicine University of California Davis Sacramento CA 95817 USA
UC Davis RISE Eye‐Pod Laboratory Department of Cell Biology and Human Anatomy University of California Davis Davis CA 95616 USA
Department of Internal Medicine School of Medicine University of California Davis Sacramento CA 95817 USA
Funding
National Cancer Institute · University of California
References (65)
Show source-provided references
1. 10.1038/nm.429310.1038/nm.4293 ↗
2. 10.1038/ng.293610.1038/ng.2936 ↗
3. 10.2176/nmc.ra.2017-001810.2176/nmc.ra.2017-0018 ↗
4. La Madrid A. M. · Front. Oncol. · 2015 · 5 · 148
5. 10.1002/adfm.20170737110.1002/adfm.201707371 ↗
6. 10.1002/adma.20180755710.1002/adma.201807557 ↗
7. 10.3390/cells704002410.3390/cells7040024 ↗
8. 10.1002/adma.20170345810.1002/adma.201703458 ↗
9. 10.1038/nrd.2015.2110.1038/nrd.2015.21 ↗
10. 10.1126/sciadv.170167910.1126/sciadv.1701679 ↗
11. 10.2217/nnm.12.18510.2217/nnm.12.185 ↗
12. 10.1007/s11095-013-1196-z10.1007/s11095-013-1196-z ↗
13. 10.1517/17425247.2012.68272610.1517/17425247.2012.682726 ↗
14. 10.1039/C5NR01408E10.1039/C5NR01408E ↗
15. 10.1002/adfm.20170396710.1002/adfm.201703967 ↗
16. 10.7150/thno.2125410.7150/thno.21254 ↗
17. 10.2174/138161282266615122115073310.2174/1381612822666151221150733 ↗
18. 10.2174/138161282266615122115073310.2174/1381612822666151221150733 ↗
19. 10.7150/thno.2125410.7150/thno.21254 ↗
20. 10.3109/1061186X.2015.102993010.3109/1061186X.2015.1029930 ↗
21. 10.1016/j.apsb.2014.03.00110.1016/j.apsb.2014.03.001 ↗
22. 10.1371/journal.pone.013965210.1371/journal.pone.0139652 ↗
23. 10.1016/j.ddtec.2016.07.00910.1016/j.ddtec.2016.07.009 ↗
24. 10.1002/adfm.20180222710.1002/adfm.201802227 ↗
25. 10.1038/s41467-017-02401-710.1038/s41467-017-02401-7 ↗
26. 10.1016/j.nano.2016.01.00410.1016/j.nano.2016.01.004 ↗
27. 10.1016/j.biomaterials.2013.08.03010.1016/j.biomaterials.2013.08.030 ↗
28. 10.1038/nrn299510.1038/nrn2995 ↗
29. 10.1016/j.ejpb.2016.12.03410.1016/j.ejpb.2016.12.034 ↗
30. 10.1126/science.116844110.1126/science.1168441 ↗
31. 10.1016/j.pharmthera.2017.02.00610.1016/j.pharmthera.2017.02.006 ↗
32. 10.1126/sciadv.160022010.1126/sciadv.1600220 ↗
33. 10.1002/adhm.20150066810.1002/adhm.201500668 ↗
34. 10.1158/0008-5472.CAN-14-072810.1158/0008-5472.CAN-14-0728 ↗
35. 10.1021/acsami.5b1186610.1021/acsami.5b11866 ↗
36. 10.1002/adma.20170505410.1002/adma.201705054 ↗
37. 10.1002/adfm.20170566810.1002/adfm.201705668 ↗
38. 10.1016/j.biomaterials.2012.02.00410.1016/j.biomaterials.2012.02.004 ↗
39. 10.1016/j.jconrel.2017.11.02610.1016/j.jconrel.2017.11.026 ↗
40. 10.1002/adfm.20170468910.1002/adfm.201704689 ↗
41. 10.1002/pro.285810.1002/pro.2858 ↗
42. 10.1126/sciadv.160051610.1126/sciadv.1600516 ↗
43. 10.1002/adma.20150290210.1002/adma.201502902 ↗
44. 10.1039/C5CS00798D10.1039/C5CS00798D ↗
45. 10.1038/nmat381910.1038/nmat3819 ↗
46. Lang T. Q. · Adv. Mater. · 2019 · 31 · 190006010.1002/adma.201900060 ↗
47. 10.7150/thno.1515610.7150/thno.15156 ↗
48. 10.1002/anie.20110714410.1002/anie.201107144 ↗
49. 10.1039/c3cc43209b10.1039/c3cc43209b ↗
50. 10.1002/anie.20090426010.1002/anie.200904260 ↗
51. 10.2337/diacare.23.10.156310.2337/diacare.23.10.1563 ↗
52. 10.1038/s41565-018-0085-310.1038/s41565-018-0085-3 ↗
53. 10.1016/j.celrep.2017.11.05510.1016/j.celrep.2017.11.055 ↗
54. 10.1074/jbc.270.39.2283610.1074/jbc.270.39.22836 ↗
55. 10.1097/00003246-199611000-0001610.1097/00003246-199611000-00016 ↗
56. 10.1161/CIRCULATIONAHA.107.74118110.1161/CIRCULATIONAHA.107.741181 ↗
57. Mora E. · Am. J. Cancer Res. · 2016 · 6 · 2416
58. 10.1200/JCO.2013.49.372610.1200/JCO.2013.49.3726 ↗
59. 10.2119/molmed.2017.0001110.2119/molmed.2017.00011 ↗
60. Mora E. · Am. J. Cancer Res. · 2016 · 6 · 2416
61. 10.1158/0008-5472.CAN-17-369110.1158/0008-5472.CAN-17-3691 ↗
62. 10.1093/neuonc/noy059.12810.1093/neuonc/noy059.128 ↗
63. 10.1038/nm.432010.1038/nm.4320 ↗
64. 10.1158/1078-0432.CCR-17-080310.1158/1078-0432.CCR-17-0803 ↗
65. 10.1016/j.bmcl.2019.06.02110.1016/j.bmcl.2019.06.021 ↗